Capital Fund Management (CFM)’s United Therapeutics UTHR Stock Holding History

Capital Fund Management (CFM)’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,800	Closed	-$247K	–	2041
2019 Q4	$247K	Buy	+2,800	New	+$246K	﹤0.01%	1674
2019 Q3	–	Sell	-3,100	Closed	-$242K	–	1912
2019 Q2	$242K	Buy	+3,100	New	+$290K	﹤0.01%	1459
2019 Q1	–	Sell	-2,000	Closed	-$218K	–	2113
2018 Q4	$218K	Buy	+2,000	New	+$232K	﹤0.01%	1727
2018 Q2	–	Sell	-9,300	Closed	-$1.04M	–	2290
2018 Q1	$1.04M	Buy	+9,300	New	+$1.18M	0.01%	1219
2015 Q3	–	Sell	-2,400	Closed	-$417K	–	1681
2015 Q2	$417K	Buy	+2,400	New	+$432K	0.01%	1146
2013 Q4	–	Sell	-4,900	Closed	-$386K	–	1852
2013 Q3	$386K	Buy	+4,900	New	+$358K	0.01%	1261

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Capital Fund Management (CFM)'s UTHR Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its United Therapeutics (UTHR) stake by 8.3% in Q2 2026, buying an estimated $2.29M and bringing the position to 53,037 shares worth $28.7M. The position accounts for 0.13% of the portfolio, ranked #190.

Capital Fund Management (CFM) first reported a position in UTHR in Q2 2013 and has held it in 32 quarters since. The position peaked at $29M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Capital Fund Management (CFM) held 53,037 shares of United Therapeutics worth $28.7M as of Q2 2026.
Capital Fund Management (CFM) bought 4,073 United Therapeutics shares in Q2 2026, an estimated $2.29M.
United Therapeutics made up 0.13% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #190 holding.
Capital Fund Management (CFM) first reported a position in United Therapeutics in Q2 2013 and has held it in 32 quarters since.
Capital Fund Management (CFM)'s United Therapeutics position peaked at $29M in Q1 2026.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.